J&J starts head-to-head PFA trial against Boston Scientific device
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free…
Cramer: The money to AI stocks is a problem, and how it can be fixed
We do not have enough money coming into this market. The funds flow only to stocks tied to…
Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company…
Johnson & Johnson Vs. Pfizer
As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify…
How The Narrative On Johnson & Johnson (JNJ) Is Shifting With New Targets And Litigation Risks
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
ICOTYDE Approval Adds New Growth Angle To Johnson & Johnson Valuation Story
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
More drugs should be over-the-counter
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter”…
Is Johnson & Johnson a Buy, Sell, or Hold in 2026?
While artificial intelligence (AI) stocks are dominating debates and headlines on Wall Street, companies in other sectors can…
A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate Reality
A dual-income couple approaching retirement with $1.2 million in savings and Social Security benefits faces a critical question:…
J&J wants to be the leader in the cancer fight. Its strategy is starting to pay off as oncology sales top $25 billion in 2025.
Last Updated: Jan. 21, 2026 at 10:14 a.m. ETFirst Published: Jan. 21, 2026 at 7:26 a.m. ET Johnson & Johnson…
Johnson & Johnson (JNJ) Q4 earnings
Johnson & Johnson said on Thursday that it has reached an agreement with the U.S. President administration to…